Loading…
← CockpitCompetitor Analysis › SECARE.ST Swedencare ABOpen in the cockpit ↗

Swedencare ABSECARE.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major
Momentum laggard 11
Mkt cap
$321M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$620,338
20-day average traded
Fwd P/E
24.9×
forward earnings
ROIC−WACC
-3.3 pp
WACC 5.0%
Hurdle
-56 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · SEKSEK 20.45
1D+2.2%
1W+5.8%
1M-13.2%
3M-7.9%
6M-24.3%
YTD-46.7%
1Y-41.2%
ATR %3.7%
52w lowhigh48.7% off high

What Swedencare does

Employees: 613

Swedencare at a glance

Size Swedencare (SECARE.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $321M, the 213th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 20.45 on 18 Nov 2026.

Performance Over six months the shares fell 24.3%, against -20.4% for the median peer and +2.8% for the Sweden market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 2.7% over the last twelve months (peer median +2.7%); the operating margin is 7.0% (peer median -1.9%).

Valuation It trades at 24.9× forward earnings against a peer median of 20.7× (2nd most expensive of 4).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +62%, so the hurdle is -56 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.3 points below its cost of capital (5.0% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 78SECARE.ST 77
Six months, rebased to 100: Swedencare against the median of its 20 peers (local-currency closes).

Swedencare financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 2.73BSEK 2.68BSEK 2.53BSEK 2.32BSEK 1.83B
Revenue growth—+6%+9%+27%—
Gross profitSEK 193MSEK 142MSEK 222MSEK 165MSEK 121M
EBITDASEK 507MSEK 452MSEK 537MSEK 475MSEK 390M
Net incomeSEK 86.6MSEK 55.5MSEK 98.9MSEK 58.6MSEK 94.5M
Free cash flowSEK 220MSEK 279MSEK 318MSEK 410MSEK 186M
Capital expenditureSEK 68.3MSEK 51.2MSEK 71.3MSEK 36.1MSEK 74.7M
Total debtSEK 1.69BSEK 1.80BSEK 1.47BSEK 1.66BSEK 1.90B

Quarterly statements and history in the cockpit →

Swedencare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%0052506576AVIR600538INO002168INDSWFTLAB1720MYX1875ALEMBICLTDSOLARARLMD300086603079SECARE.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Swedencare is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×100×200×300×368A1875SOLARASECARE.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Swedencare is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%368A0021681720000790301509MYXALEMBICLTDSOLARA301331300086603079SECARE.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Swedencare is the large dot.

Swedencare competitors and peer comparison

How Swedencare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Swedencare against its 20 peers (data as of 18 Nov 2026)
MeasureSECARE.STPeer medianRank in peer set
1-month return-13.2%-6.1%5th lowest of 21
6-month return-24.3%-20.4%9th lowest of 21
Distance from 52-week high-48.7%-37.5%6th lowest of 21
Revenue growth (TTM)+2.7%+2.7%10th highest of 19
Operating margin7.0%-1.9%6th highest of 19
Forward P/E24.9×20.7×2nd most expensive of 4
Growth the price implies (Req g, 7 yrs)6.1%14.3%4th least demanding of 12
Growth delivered (Del g)+62.1%-0.3%highest of 12
Hurdle (Req g minus delivered)-56.0 pp+17.6 ppleast demanding of 12
ROIC minus cost of capital-3.3 pp-7.7 pp6th highest of 18
EV / EBITDA9.6×15.8×3rd cheapest of 7
Net debt / EBITDA3.2×-1.8×2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Swedencare SECARE.STSweden$321M-24%+3%7%24.9×6.1%+62.1%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%n/an/an/a
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%n/an/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%n/an/an/a
Kitazato 368A.TJapan$317M+7%+9%52%12.2×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%n/an/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%n/a14.3%-14.0%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%n/an/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%n/a-11.5%+10.3%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%n/a27.5%-6.4%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%n/a9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%n/a19.0%-0.9%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%288.2×n/an/a
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%n/a44.3%+26.7%
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%20.7×38.3%-3.2%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%n/a14.0%+7.3%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%n/an/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%n/a56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%n/a4.6%-0.3%

Questions

Which companies are Swedencare's closest peers?
The cockpit's peer set: GC Corp. (005250.KS), Foresee Pharmaceuticals (6576.TWO), Atea Pharmaceuticals (AVIR), Beihai Gofar Chuanshan Biological (600538.SS), Kitazato (368A.T), Inovio Pharmaceuticals (INO), Chongqing Hifuture Information Technology (002168.SZ), Ind-Swift Laboratories (INDSWFTLAB.NS).
Is Swedencare expensive compared with its peers?
On forward p/e it trades at 24.9× against a peer median of 20.7×, 2nd most expensive of 4 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +62%, so the hurdle is -56 pp: the price already allows for a slowdown.
How has Swedencare stock performed?
Over six months to 18 Nov 2026 the shares returned -24.3% against -20.4% for the median peer; over one year -41.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.